Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2020 Filed Nov 9, 2020 14:21 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 886 | $214.42 | $189,976.12 |
DisclosureSEC source: 0001127602-20-028415 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,221.1258 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 14:21 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 2,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028415 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,107.1258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 14:06 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
SaleCommon Stock | 1,500 | $214.14 | $321,203.55 |
DisclosureSEC source: 0001127602-20-028306 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,698 Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:47 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028192 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 Underlying: Common Stock · 9,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units will vest on November 1, 2021; and 40% of the Restricted Stock Units will vest on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that may adjust the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units will vest on November 1, 2021; and 40% of the Restricted Stock Units will vest on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that may adjust the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:47 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 4,034 | $207.23 | $835,965.82 |
DisclosureSEC source: 0001127602-20-028192 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,114 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:47 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 9,024 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028192 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:43 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028188 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,534 Underlying: Common Stock · 2,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:43 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 885 | $207.23 | $183,398.55 |
DisclosureSEC source: 0001127602-20-028188 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,810 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:43 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 2,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028188 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:40 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028182 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,602 Underlying: Common Stock · 2,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:40 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 895 | $207.23 | $185,470.85 |
DisclosureSEC source: 0001127602-20-028182 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,198 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:40 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 2,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028182 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 17:42 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-025822 · form4.xml · derivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,218 Underlying: Common Stock · 970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on 9/25/2020. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on 9/25/2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 17:42 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 289 | $180.99 | $52,306.11 |
DisclosureSEC source: 0001127602-20-025822 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097.1258 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 89.7355 shares acquired on June 30, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 17:42 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-025822 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,386.1258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 89.7355 shares acquired on June 30, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| September 21, 2020 Filed Jan 28, 2021 17:11 UTC |
Williams R SandersDirector
|
GiftCommon Stock | 1,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002786 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,946 Read SEC document |
| August 01, 2020 Filed Aug 18, 2020 12:20 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023737 · form4.xml · derivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 Underlying: Common Stock · 150 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 8/1/21. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 8/1/21. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:25 UTC |
Williams R SandersDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 1,300 | $0.00 Strike: $98.49 | $0.00 |
DisclosureSEC source: 0001127602-20-021339 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:25 UTC |
Williams R SandersDirector
|
SaleCommon Stock | 1,300 | $173.12 | $225,056.00 |
DisclosureSEC source: 0001127602-20-021339 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:25 UTC |
Williams R SandersDirector
|
Exercise / conversionCommon Stock | 1,300 | $98.49 | $128,037.00 |
DisclosureSEC source: 0001127602-20-021339 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 13:38 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 435 | $170.00 | $73,950.00 |
DisclosureSEC source: 0001127602-20-021246 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,043.8788 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 14:06 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 436 | $160.33 | $69,903.88 |
DisclosureSEC source: 0001127602-20-020381 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,478.8788 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 14:06 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 436 | $160.33 | $69,903.88 |
DisclosureSEC source: 0001127602-20-020381 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,914.8788 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:05 UTC |
KING DAVID PDirector
|
SaleCommon Stock | 31,250 | $160.00 | $5,000,000.00 |
DisclosureSEC source: 0001127602-20-015690 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,554.1345 Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:21 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-013389 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,608 Underlying: Common Stock · 1,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on April 3, 2019. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on April 3, 2019. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:21 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 372 | $113.31 | $42,151.32 |
DisclosureSEC source: 0001127602-20-013389 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,087 F1 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:21 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-013389 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:40 UTC |
KING DAVID PDirector
|
Tax withholdingCommon Stock | 24,583 | $131.95 | $3,243,726.85 |
DisclosureSEC source: 0001127602-20-012389 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,804.1345 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:40 UTC |
KING DAVID PDirector
|
GrantCommon Stock | 54,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012389 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,387.1345 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, while the reporting person held the position of Chief Executive Officer and President, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:39 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 1,106 | $131.95 | $145,936.70 |
DisclosureSEC source: 0001127602-20-012385 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350.8788 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:39 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantCommon Stock | 3,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012385 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,456.8788 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:33 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 5,787 | $131.95 | $763,594.65 |
DisclosureSEC source: 0001127602-20-012380 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,124 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:33 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantCommon Stock | 12,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012380 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,911 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:29 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 1,014 | $131.95 | $133,797.30 |
DisclosureSEC source: 0001127602-20-012377 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,449 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:29 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantCommon Stock | 3,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012377 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,463 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:28 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 1,153 | $131.95 | $152,138.35 |
DisclosureSEC source: 0001127602-20-012376 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213.3565 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:28 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantCommon Stock | 3,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012376 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,366.3565 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:23 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 1,695 | $131.95 | $223,655.25 |
DisclosureSEC source: 0001127602-20-012373 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:23 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantCommon Stock | 3,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012373 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,238 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| March 10, 2020 Filed May 4, 2020 14:18 UTC |
Seltz Judith CEVP, CHRO
|
PurchaseCommon Stock | 330 | $168.56 | $55,624.80 |
DisclosureSEC source: 0001127602-20-015115 · form4.xml · nonDerivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:00 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantNon-qualified Stock Options · Derivative | 3,600 | $0.00 Strike: $187.96 | $0.00 |
DisclosureSEC source: 0001127602-20-009455 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2030-02-03 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:00 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantRestricted Stock Unit · Derivative | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009455 · form4.xml · derivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,140 Underlying: Common Stock · 1,340 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units fully vest on March 2, 2023. F3 · derivative.expiration_date: The Restricted Stock Units fully vest on March 2, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:00 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantRestricted Stock Unit · Derivative | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009455 · form4.xml · derivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. Read SEC document |
| February 28, 2020 Filed May 4, 2020 14:18 UTC |
Seltz Judith CEVP, CHRO
|
PurchaseCommon Stock | 250 | $174.94 | $43,735.00 |
DisclosureSEC source: 0001127602-20-015115 · form4.xml · nonDerivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:59 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
SaleCommon Stock | 297 | $189.65 | $56,325.72 |
DisclosureSEC source: 0001127602-20-007522 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 20:52 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 3,100 | $0.00 Strike: $77.19 | $0.00 |
DisclosureSEC source: 0001127602-20-006926 · form4.xml · derivative · entry 3 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,100 shares Expires 2020-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 20:52 UTC |
BELINGARD JEAN-LUCDirector
|
SaleCommon Stock | 26,479 | $189.76 | $5,024,750.36 |
DisclosureSEC source: 0001127602-20-006926 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,682 F1 · price: The price of $189.7636 per share represents a weighted average of sales prices ranging from $189.54 to $189.917 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 20:52 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 3,100 | $77.19 | $239,289.00 |
DisclosureSEC source: 0001127602-20-006926 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
SaleCommon Stock | 103 | $188.49 | $19,414.47 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 6 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,735.8788 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
SaleCommon Stock | 105 | $188.49 | $19,791.45 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,838.8788 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.